A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Eligible age
30–80 yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
Sponsor: Appello Pharmaceuticals, Inc.
Where it's recruiting
Little Rock
Carlsbad · Los Alamitos · Los Angeles · Palo Alto
Englewood
Boca Raton · Hallandale · Miami · Orlando …
Augusta
Indianapolis
Kansas City
Lexington
Boston
Ann Arbor · Farmington Hills
Albuquerque
New York
Source: ClinicalTrials.gov · NCT07432958 · last updated 2026-10-28